Circassia Pharmaceuticals (LON:CIR) had its target price decreased by Royal Bank of Canada from GBX 86 ($1.12) to GBX 81 ($1.06) in a research report sent to investors on Wednesday morning. Royal Bank of Canada currently has a sector performer rating on the stock.

A number of other equities analysts have also recently issued reports on the company. Peel Hunt restated a buy rating on shares of Circassia Pharmaceuticals in a report on Wednesday, October 3rd. Numis Securities restated a buy rating and set a GBX 140 ($1.83) target price on shares of Circassia Pharmaceuticals in a report on Thursday, September 27th.

Shares of CIR opened at GBX 65.15 ($0.85) on Wednesday.

Circassia Pharmaceuticals Company Profile

Circassia Pharmaceuticals plc, a specialty biopharmaceutical company, focuses on the development and commercialization of products for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It markets novel NIOX asthma management products directly to specialists in the United States, the United Kingdom, and Germany, as well as through a network of partners internationally.

Read More: How to Use a Moving Average for TradingĀ 

Receive News & Ratings for Circassia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Circassia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.